In the last two years, COVID-19 pandemic caused by SARS-CoV-2 has created a mass destruction among humanity causing a major health crisis around the world. With the emergence of new strains of the virus, lack of targeted drugs and antimicrobial resistance, there is a dire need to discover specific antiviral with minimum side effects targeted against COVID-19. The present study evaluates the antiviral efficacy of a novel Ayurvedic polyherbal formulation, NOQ19, composed of a 13 well known herbs, in a cell-based setting. Vero E6 (CL1008), the African green monkey kidney epithelial cell, were infected with SARS-CoV-2 virus (isolate USA–WA1/2020) in a 96 well-plate. NOQ19 test material was diluted at different concentration: 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml and 0.9 mg/ml. These different concentrations of NOQ19 were added to infected cells respectively and incubated for 3 days in 5% CO2 incubator. Remdesivir was used as a positive control. The cells were finally fixed with formaldehyde, stained with crystal violet and plaques were visualized. The number of plaques were counted to determine the PFU(plaque forming units)/ml. The results of the present study demonstrated an excellent an antiviral efficacy of NOQ19 at 0.9 mg/ml concentration, eliminating 100% virus. The IC50 of the drug was found to be 0.2 mg/ml. There is limited data around pre-clinical efficacy of polyherbal Ayurvedic drugs. Ayurvedic and herbal formations need to be tested in a preclinical setting to support the human data. The results of the present study demonstrated viral load reduction using NOQ19 in Vero E6 cell lines infected with SARS-CoV-2 virus. These result along with other preclinical and clinical trials could further evaluate the efficacy of NOQ19 as a potential therapeutic option in the fighting the COVID-19 challenge.
21 April 2026 in Clinical Child Psychology and Psychiatry
Background: The rapid technological growth and the ease of access to Internet to the current generation population (Generation Z, alpha) right from their early days of life, has its both advantages and disadvantages. The present epidemiological study evaluates the impact of yoga and meditation practices on the teenagers’ mental health and lifestyle choices. Methods: The total sample size is 425, of age group 13–19, 237 were practicing either yoga, meditation or both, while 188 practiced neither meditation nor yoga. Several different parameters were assessed via the PROMIS pediatric forms. Several lifestyle habits were also assessed using subjective questions. Results: Our study has demonstrated that teens who practiced yoga and meditation had a significantly positive effect on the parameters such as positive affect ( p value <.001), global health ( p value = .03) and cognitive health ( p value = .02) compared to their peers who did not practice any yoga or meditation. It was also shown a negative effect on parameters such as psychological stress experiences ( p value = .06), sleep related problems ( p value = .41). Conclusions: Along with the mental and cognitive health, the decisions and choices made by the teenagers who practice yoga and meditation are shown to be better than their peers in this Indian epidemiological study.
20 January 2025 in Clinical Child Psychology and Psychiatry
Adolescence is a critical life period that marks the transition into adulthood. This novel study aims to evaluate the benefits of 4- day intervention, Sudarshan Kriya Yoga (SKY), a breathing technique, on the emotional, mental, and cognitive health of teenagers. Open label trial tests were administered at pre-intervention, immediately after SKY, and after 40 days of SKY practice. Cognitive abilities of 275 adolescents were tested using the Six letter cancellation test. Mental well-being was assessed using the World Health Organization-five Index (WHO-5), and Emotional well-being using the Strength and Difficulty Questionnaire (SDQ) questionnaire. The Results were analyzed using a paired-sample t test. The results showed an improvement in cognitive abilities for 71% of the study population as measured by the six-letter cancellation test, better mental health scores for 86%, and better SDQ scores for 95% of the population after SKY practice.
Background The COVID-19 pandemic, caused by the human coronavirus SARS- CoV-2, has led to millions of deaths across the globe. Not only is the SARS-CoV-2 virus highly infectious, it also mutates very easily. This creates additional challenges for development of robust therapeutic solutions. Along with modern system of healthcare, there is a definite need for exploring natural plant based antiviral compounds directed against the SARS CoV-2 virus. Objective The present observational study investigates the efficacy of an Ayurvedic polyherbal formulation of 19 ingredients, NOQ19, in the management of COVID-19. Methodology: A single arm, single centric, open label study design was adopted for this feasibility study. 161 RT-PCR positive COVID-19 patients were enrolled. The enrolled participants were provided the Ayurvedic intervention, 2 tablets of NOQ19, thrice daily along with the standard of care treatment. Follow up COVID-19 RT- PCR tests were conducted on Day 5, Day 10 and Day 14, or until the patient turned negative. The time required for testing negative on the RT-PCR test or becoming asymptomatic was noted. Results A subjective analysis demonstrated that 74% of patients turned RT-PCR negative within 5 days of taking NOQ19. Additionally, 98% of the subjects turned RT-PCR Negative on Day 10 after taking NOQ19 in addition to the standard of care treatment of Vitamin C, Zinc and antipyretic (as necessary). None of the participants reported any adverse or side effects to the medication. Conclusion NOQ19 Ayurvedic polyherbal formulation can be an effective and safe option for the symptomatic management of COVID-19.
Background: More than 6.2 million people have died already from COVID-19. Drug resistance and relapse cases from first generation therapeutics calls for development of new drugs in alternative medicine. Complementary and Alternative Medicines (CAM) that include herbal remedies and phytochemicals are usually not fully integrated into mainstream healthcare systems. The study proposes a CAM remedy, a new polyherbal formulation ‘NAOQ19’ against the SARS-CoV-2. Methods: The present study consists of invitro and invivo evaluation of NAOQ19 against SARS-CoV-2 infection. First, invitro testing of NAOQ19 anti-viral activity was carried out on three relevant cell lines: Vero E6, A549ACE2 and Huh 7.5.1 ACE2TMPRSS2. Next, animal model testing of NAOQ19 was performed in Syrian golden hamsters along with positive control Remdesivir and infection control for 3 days to determine the efficacy and safety of the formulation. Finally, a double blind randomized clinical trial with mild to moderate COVID-19 infected patients were evaluated to test the efficacy of NAOQ19 in human settings. Results: This study demonstrated a strong anti-viral (low EC50) activity in cell culture with live virus and exhibits reduced plaque forming units (high antiviral activity) in the Syrian golden hamster model. Moreover, in the clinical trials, NAOQ19 shows high efficacy demonstrating early recovery and reduced levels of inflammatory biomarkers among COVID-19 infected patients. Conclusion: This novel polyherbal formulation NAOQ19, demonstrates strong anti-viral activity in preclinical and clinical study; thereby proving its candidacy as a low-cost alternative medicine with minimal adverse effects.